4SC attending 3 upcoming investor and scientific conferences
Planegg-Martinsried, Germany, 15 May 2017 – 4SC AG (4SC, FSE Prime Standard: VSC) today announced that 4SC will be attending upcoming investor and scientific conferences. 4SC’s attendees will be available for one-on-one meetings at these conferences.
Bio€quity Europe 2017
Jason Loveridge, Ph.D., CEO
22 and 23 May 2017
Marriott Rive Gauche
Paris, France
2017 American Society of Clinical Oncology (ASCO) Annual Meeting
Frank Hermann, M.D., Chief Development Officer
Susanne Danhauser-Riedl, M.D., Chief Medical Officer of 4SC
2 to 6 June 2017
McCormick Place
Chicago, USA
Annual Cancer Immunotherapy and Combinations Congress, as part of the World Preclinical Congress (WPC)
Svetlana Hamm, Ph.D., Head of Translational Pharmacology
13 June at 4:05 p.m. EDT, oral presentation “Epigenetic priming with HDAC inhibitor resminostat sensitizes cancer to NK cell based immunotherapy”
13 and 14 June 2017
The Westin Copley Place
Boston, USA
Further information
About 4SC
4SC AG is a clinical-stage biopharmaceutical company developing small-molecule drugs that can target key indications in cancer with high unmet medical needs through epigenetic mechanisms. Such drugs are intended to provide patients with innovative treatment options that are more tolerable and efficacious than existing therapies and provide a better quality of life. 4SC’s core assets include resminostat, 4SC-202 and 4SC-208.
4SC’s pipeline is protected by a comprehensive portfolio of patents and comprises promising products that are in various stages of preclinical and clinical development. 4SC’s aim is to generate future growth and enhance its enterprise value by entering into partnerships with pharmaceutical and biotech companies and/or the eventual marketing and sales of approved drugs in select territories by 4SC itself. Founded in 1997, 4SC had 48 employees as of 31 March 2017. 4SC has been listed on the Prime Standard of the Frankfurt Stock Exchange since December 2005.
Forward-looking information
Information set forth in this press release contains forward-looking statements, which involve risks and uncertainties. The forward-looking statements contained herein represent the judgement of 4SC as of the date of this press release. Such forward-looking statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond 4SC’s control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. 4SC expressly disclaims any obligation or undertaking to release any updates or revisions to any such statements to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based.
The Ruth Group
Robert Flamm, Ph.D., email hidden; JavaScript is required, +1 646-536-7017
MC Services
Katja Arnold, email hidden; JavaScript is required, +49 89 210228-40